GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

NewsGuard 100/100 Score

GSK (LSE/NYSE: GSK) today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S.

Cheryl MacDiarmid, Vice President of GSK's General Medicine business said, "With approximately 21 million adults diagnosed with diabetes in the US, and up to 95 percent of those patients living with type 2 diabetes, we're excited that for the appropriate patients Tanzeum is now available as a treatment option for healthcare professionals."

Tanzeum, a glucagon-like peptide-1 (GLP-1) receptor agonist, is a once weekly option for patients, in combination with some other glucose-lowering medicines. The medicine was approved by the FDA on April 15, 2014 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Tanzeum is not recommended as first-line therapy for patients inadequately controlled on diet and exercise. Tanzeum has not been studied in patients with a history of pancreatitis. Other antidiabetic therapies should be considered in patients with a history of pancreatitis. Tanzeum is not indicated in the treatment of patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis. Tanzeum is not a substitute for insulin in these patients. Tanzeum has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis. The use of Tanzeum is not recommended in patients with pre-existing severe gastrointestinal disease. Tanzeum has not been studied in combination with prandial insulin.

MacDiarmid continued, "GSK has a commitment to taking a responsible approach to pricing. Tanzeum has been priced in line with this commitment."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Combined exercise and diet interventions show potential in improving ovarian cancer patients' outcomes